The study systematically reviewed the respiratory effects of e-cigarette (EC) use, distinguishing between dual use, exclusive use, and naïve use. Twelve systematic reviews were analyzed No significant changes in respiratory
On Saturday 16th November, Prof. Riccardo Polosa joined the 2024 Annual Cardiorenal, Obesity & Metabolic Health Summit held in Fujairah (UAE) to deliver an oral presentation on diabetes, smoking cessation
New Partnerships for the International Research Project Diasmoke Thanks to additional funding from the PNRR Heal Italia, the first national supply chain dedicated to research and innovation in Precision Medicine,
The DiaSmokeFree Working Group send a letter to the American Diabetes Association (ADA) expressing concern and seeking correction of a couple of statements in the ADA guidelines regarding the use
During the 2023 edition of the GFN, a pool of international diabetologists, coordinated by prof. Riccardo Polosa, addressed the issue of cigarette smoking among diabetes patients, setting new international treatment
GFN 2023 will start tomorrow in Varsavia. The 10th edition of the Global Forum on Nicotine, organised from 21st to 24th June, will host events dedicated to harm reduction research.
Diabetes is a chronic disease that can be the cause of serious health conditions and greatly reduce people quality of life. Conventional cigarette smoke is a very high risk factor
Diasmoke 2.0 is a CoEHAR research project that aims to assess health improvements and changes in cardiovascular risk factors in smokers with Type 2 Diabetes who switch to combustion-free nicotine
A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus LINK TO
LINK TO THE STUDY Quitting smoking can reduce cardiovascular and kidney failure risks. However, it can lead to side effects such as weight gain. A scoping review conducted by a
